Mobile

Study to assess the effects of a 3 week therapy each with QVA149 versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe COPD

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-001477-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective:  To demonstrate that QVA149 (110/50 μg q.d.) is superior compared to placebo on peak inspiratory capacity (IC) after 21 days of treatment in patients with moderate to severe COPD. Co-primary objective:  To evaluate whether QVA149 is superior to placebo with respect to average physical activity level as defined by average daily activity-related energy consumption [Kcal/day].

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens